We do not generate profits every quarter. On the contrary, we have reported losses for years together.
Because our product generation batch time is not a few hours, or days or weeks. It is years. About 13-15 years.
And even after that, we are not certain that we will generate any returns at all.
THIS IS SUVEN LIFE SCIENCES.
We are innovators.
Mavericks who delve into the darkness of the unknown. Undertake unfamiliar journeys with the hope of creating something that never existed on the Earth. And leave our mark on the world for generations.
We focus on 'Return on Life' as opposed to 'Return on Investment' for when our efforts see the light of day, millions across the world will live better lives.
We patiently persevere every day, every month, every year, with the passion of Moving Closer to End point.
FOR THAT IS WHEN OUR EFFORTS WILL SEE THE
FIRST RAY OF THE SUN'S LIGHT.
Established in 2003,
13
we are an NCE
developer based in
India who is patiently
molecules...
developing...
that address neuro- degenerative disorders such as cognitive impairment associated with Alzheimer's disease, Attention Deficient Hyperactivity Disorder (ADHD), Huntington's disease, Parkinson, Bipolar disorder and Schizophrenia and Major Depressive Disorders (MDD), pain and sleep disorders etc.
002
CLOSER
MOVING
Out of the...
48
inventions...
H
We have 1,000 invested more
than... crore...
that we ideated, evaluated and brainstormed on over our two-decadal journey.
in our R&D efforts in the ardent hope of moving closer to the end point.
And this investment is yet to generate any return yet.
We are the only Indian NCE-focused player with this large basket of molecules addressing CNS Disorders.
SUVEN LIFE SCIENCES LIMITED
001
CORPORATE
019
STATUTORY
096
FINANCIAL
003
ANNUAL REPORT 2022-23
OVERVIEW
REPORTS
STATEMENTS
Attachments
Original Link
Original Document
Permalink
Disclaimer
Suven Life Sciences Limited published this content on 12 July 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 July 2023 08:16:05 UTC.
Suven Life Sciences Limited is an India-based biopharmaceutical company. The Company is engaged in the drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. It operates through the research and development services segment. Its drug discovery & research/clinical pipeline include Masupirdine (SUVN-502) Neuropsychiatric Symptoms in Alzheimer's, Masupirdine (SUVN-502) Cognitive deficits in AD, Samelisant (SUVN-G3031) Narcolepsy, Samelisant (SUVN-G3031) Cognitive Disorders, Ropanicant (SUVN-911) Depressive Disorders, Usmarapride (SUVN-D4010), Cognitive Disorders, SUVN-I6107, Cognitive Disorders and Schizophrenia, SUVN-M8036, Psychiatric Disorders, and SUVN-D1044 Gastrointestinal Disorders. Its drug discovery & development support services (DDDSS) include synthetic and medicinal chemistry, analytical chemistry, in vitro biology, ADME, pharmacology, toxicology, bioanalysis, and NCE formulations.
SUVEN LIFE SCIENCES LIMITED 
